Newsroom

IsoRay Announces Second Quarter Fiscal 2017 Financial Results

Management Continues to Expect Stronger Second Half of Fiscal 2017 RICHLAND, Wash., Feb. 8, 2017 /PRNewswire/ --­­ IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of...

read more

IsoRay Announces First Quarter Fiscal 2017 Financial Results

Management Continues to Expect Stronger Second Half of Fiscal 2017 RICHLAND, Wash., Nov. 8, 2016 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of...

read more

IsoRay Reports Second Quarter Fiscal 2016 Financial Results

12% Revenue Growth in The 2nd Quarter 2016 Over 2nd Quarter 2015 RICHLAND, Wash., Feb. 10, 2016 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of...

read more

Investor Relations:

Mark Levin

Global IR Group
(501) 255-1910

Media and Public Relations:

Sharon Schultz
(302) 539-3747